Company: CRL
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001100682-25-000021
Chunk: 29

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 2
Chunk 29
---
 our DSA reportable segment. 

Net income available to Charles River Laboratories International, Inc., common shareholders decreased to $25.5 million in the three months ended March 29, 2025, from $67.3 million in the corresponding period of 2024. The decreases in net income available to common shareholders were due principally to the decreases in operating income described above.

During the three months ended March 29, 2025, our cash flows from operations were $171.7 million compared with $129.9 million for the same period in 2024. The increase was primarily driven by lower payments of variable compensation and favorable timing of payments to our suppliers and vendors, partially offset by higher purchases of inventory to support our DSA reportable segment.

Three Months Ended March 29, 2025 Compared to Three Months Ended March 30, 2024

Revenue and Operating Income

The following tables present consolidated revenue by type and by reportable segment:

Three Months EndedMarch 29, 2025March 30, 2024$ change% change(in thousands, except percentages)Service revenue$797,923 $816,862 $(18,939)(2.3)%Product revenue186,245 194,698 (8,453)(4.3)%Total revenue$984,168 $1,011,560 $(27,392)(2.7)%

Three Months EndedMarch 29, 2025March 30, 2024$ change% changeImpact of FX(in thousands, except percentages)RMS$213,073 $220,907 $(7,834)(3.5)%(1.0)%DSA592,609 605,452 (12,843)(2.1)%(0.6)%Manufacturing178,486 185,201 (6,715)(3.6)%(1.4)%Total revenue$984,168 $1,011,560 $(27,392)(2.7)%(0.9)%

26 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The following table presents operating income by reportable segment:

Three Months EndedMarch 29, 2025March 30, 2024$ change% changeImpact of FX(in thousands, except percentages)RMS$43,605 $43,149 $456 1.1 %(2.0)%DSA93,952 114,839 (20,